Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate the effect of certolizumab pegol (CZP) on the quality of sperm obtained from healthy male volunteers.


Clinical Trial Description

CZP is a PEGylated humanized Fab' fragment with specificity for human tumor necrosis factor alpha (TNFα). Evidence suggests that modulation of TNFα signaling may affect male spermatogenesis. Therefore, this study will compare semen quality parameters before and after a single 400 mg dose of CZP, or matched placebo. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)


Related Conditions & MeSH terms


NCT number NCT01091220
Study type Interventional
Source UCB Pharma
Contact
Status Completed
Phase Phase 1
Start date March 2010
Completion date March 2011

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06353880 - Obesity With Sperm Quality in Men With Fertility Need
Completed NCT01560065 - Effect of Treatment With Myo-inositol on Human Semen Parameters in Patients Undergoing In Vitro Fertilization Cycles Phase 4